Outcomes following heart or bilateral-lung transplantation from donors who died of drug toxicity in British Columbia, Canada

Clin Transplant. 2023 Mar;37(3):e14866. doi: 10.1111/ctr.14866. Epub 2022 Dec 28.

Abstract

Introduction: The illicit drug toxicity (overdose) crisis has worsened across Canada; between 2016 and 2021, more than 28,000 individuals have died of drug toxicity. Organ donation from persons who experience drug toxicity death (DTD) has increased in recent years. This study examines whether survival after heart or bilateral-lung transplantation differed by donor cause of death.

Methods: We studied transplant recipients in British Columbia who received heart (N = 110) or bilateral-lung (N = 223) transplantation from deceased donors aged 12-70 years between 2013 and 2019. Transplant recipient survival was compared by donor cause of death from drug toxicity or other. Five-year Kaplan-Meier estimates of survival and 3-year inverse probability treatment weighted Cox proportional hazards models were conducted.

Results: DTD donors made up 36% (40/110) of heart and 24% (54/223) of bilateral-lung transplantations. DTD donors were more likely to be young, white, and male. Unadjusted 5-year recipient survival was similar by donor cause of death (heart: 87% for DTD and 86% for non-DTD, p = .75; bilateral- lung: 80% for DTD and 76% for non-DTD, p = .65). Adjusted risk of mortality at 3-years post-transplant was similar between recipients of DTD and non-DTD donor heart (hazard ratio [HR]: .94, 95% confidence interval (CI): .22-4.07, p = .938) and bilateral-lung (HR: 1.06, 95% CI: .41-2.70, p = .908).

Conclusion: Recipient survival after heart or bilateral-lung transplantation from DTD donors and non-DTD donors was similar. Donation from DTD donors is safe and should be considered more broadly to increase organ donation.

Keywords: drug overdose; drug toxicity; heart transplantation; lung transplantation; opiate overdose.

MeSH terms

  • British Columbia
  • Drug-Related Side Effects and Adverse Reactions*
  • Graft Survival
  • Heart Transplantation*
  • Humans
  • Lung Transplantation*
  • Male
  • Retrospective Studies
  • Tissue Donors
  • Tissue and Organ Procurement*